Workflow
康泰生物实控人前妻减持套现7435万元 近五年共募50亿

Core Viewpoint - The announcement details a share reduction plan by Yuan Liping, a significant shareholder of Kangtai Biological, which will not affect the company's control or governance structure [1][3]. Shareholder Changes - Yuan Liping plans to reduce her holdings by up to 11,160,000 shares, representing 1.00% of the total share capital, within three months from the announcement date [1]. - As of July 24, 2025, Yuan Liping has already reduced her holdings by 4,307,904 shares, which is 0.38% of the total share capital, realizing approximately 74.35 million yuan [1]. - Prior to this reduction, Yuan Liping held 137,331,675 shares (19.61% of total capital), and after the reduction, she holds 197,422,776 shares (17.68% of total capital) [1]. Control and Governance - The reduction in shares will not lead to a change in the company's control or significantly impact its governance structure [3]. - Before the reduction, Yuan Liping and other associated parties held a combined total of 339,099,830 shares (48.42% of total capital), which decreased to 530,121,967 shares (47.46% of total capital) after the reduction [2]. Fundraising Activities - Kangtai Biological raised a total of 3 billion yuan through a private placement of shares in 2020, with a net amount of approximately 2.985 billion yuan after expenses [3]. - In 2021, the company issued 20 million convertible bonds, raising a total of 2 billion yuan, with a net amount of approximately 1.98966 billion yuan after expenses [4]. - Over the past five years, Kangtai Biological has cumulatively raised 5 billion yuan [5].